{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:04:04Z","timestamp":1790935444821,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2004,4,8]],"date-time":"2004-04-08T00:00:00Z","timestamp":1081382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1007\/s00198-004-1602-9","type":"journal-article","created":{"date-parts":[[2004,4,7]],"date-time":"2004-04-07T13:31:56Z","timestamp":1081344716000},"page":"792-798","source":"Crossref","is-referenced-by-count":215,"title":["Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study"],"prefix":"10.1007","volume":"15","author":[{"name":"For the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Delmas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. R.","family":"Recker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"C. H.","family":"Chesnut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Skag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Stakkestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Emkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gilbride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. C.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,4,8]]},"reference":[{"key":"1602_CR1","doi-asserted-by":"crossref","unstructured":"Garnero P, Delmas PD (2001) Biochemical markers of bone turnover in osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, vol 2. Academic Press, San Diego, pp\u00a0459\u2013477","DOI":"10.1016\/B978-012470862-4\/50061-1"},{"key":"1602_CR2","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","volume":"359","author":"Kanis","year":"2002","unstructured":"Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929\u22121936","journal-title":"Lancet"},{"key":"1602_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s001980050009","volume":"11","author":"Ross","year":"2000","unstructured":"Ross PD, Kress BC, Parson RE et al. (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 11:76\u221282","journal-title":"Osteoporos Int"},{"key":"1602_CR4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bmj.312.7029.482","volume":"312","author":"van","year":"1996","unstructured":"van Daele PLA, Seibel MJ, Burger H et al. (1996) Case-control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ 312:482\u2212483","journal-title":"BMJ"},{"key":"1602_CR5","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","volume":"11","author":"Garnero","year":"1996","unstructured":"Garnero P, Hausherr E, Chapuy M-C et al. (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 11:1531\u22121538","journal-title":"J Bone Miner Res"},{"key":"1602_CR6","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/bmj.303.6808.961","volume":"303","author":"Hansen","year":"1991","unstructured":"Hansen MA, Overgaard K, Riis BJ, Christiansen C (1991) Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12\u00a0year study. BMJ 303:961\u2212964","journal-title":"BMJ"},{"key":"1602_CR7","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","volume":"15","author":"Garnero","year":"2000","unstructured":"Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526\u22121536","journal-title":"J Bone Miner Res"},{"key":"1602_CR8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/edrv.23.1.0453","volume":"23","author":"Marcus","year":"2002","unstructured":"Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes with fracture as endpoint. Endocr Rev 23:16\u221237","journal-title":"Endocr Rev"},{"key":"1602_CR9","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","volume":"42","author":"Hochberg","year":"1999","unstructured":"Hochberg MC, Ross PD, Black D et al. (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246\u22121254","journal-title":"Arthritis Rheum"},{"key":"1602_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1210\/jc.85.1.231","volume":"85","author":"Wasnich","year":"2000","unstructured":"Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents is related to changes in bone density. J Clin Endocrinol Metab 85:231\u2212236","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR11","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","volume":"286","author":"Siris","year":"2001","unstructured":"Siris ES, Miller PD, Barrett-Connor E et al. (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA 286:2815\u22122822","journal-title":"JAMA"},{"key":"1602_CR12","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254\u22121259","journal-title":"BMJ"},{"key":"1602_CR13","unstructured":"Ravn P (2001) Prediction of response in bone mass by biochemical markers of bone turnover during antiresorptive therapy for prevention of osteoporosis. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers: biochemical and clinical perspectives; Martin Dunitz, London, pp\u00a0167\u2212178"},{"key":"1602_CR14","unstructured":"Gundberg CM (2001) Osteocalcin. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers: biochemical and clinical perspectives. Martin Dunitz, London; pp\u00a065\u221272"},{"key":"1602_CR15","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","volume":"359","author":"Delmas","year":"2002","unstructured":"Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018\u20132026","journal-title":"Lancet"},{"key":"1602_CR16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"1602_CR17","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"1602_CR18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1602_CR19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorenson OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"1602_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"1602_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","volume":"12","author":"Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G et al. (2000) Therapeutic equivalence of alendronate 70\u00a0mg once-weekly and alendronate 10\u00a0mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12:1\u201312","journal-title":"Aging Clin Exp Res"},{"key":"1602_CR22","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","volume":"16","author":"Riis","year":"2001","unstructured":"Riis BJ, Ise J, Von Stein T, Bagger Y, Christiansen C (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871\u22121878","journal-title":"J Bone Miner Res"},{"key":"1602_CR23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","volume":"103","author":"Thi\u00e9baud","year":"1997","unstructured":"Thi\u00e9baud D, Burckhardt P, Kriegbaum H et al. (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298\u2212307","journal-title":"Am J Med"},{"key":"1602_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653\u2212661","journal-title":"N Engl J Med"},{"key":"1602_CR25","first-page":"S32","volume":"13","author":"Kendler","year":"2002","unstructured":"Kendler DL, Diez-Perez A, Gaines KA, Verbruggen N, Melton ME (2002) Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study. Osteoporos Int 13:S32 (Abstract P92SA)","journal-title":"Osteoporos Int"},{"key":"1602_CR26","first-page":"S36","volume":"13","author":"Palmisano","year":"2002","unstructured":"Palmisano J, Melton M, Lewiecki EM et al. (2002) Preference study of alendronate 70\u00a0mg once weekly and alendronate 10\u00a0mg once daily in postmenopausal women with osteoporosis. Osteoporos Int 13:S36 (Abstract P103MO)","journal-title":"Osteoporos Int"},{"key":"1602_CR27","unstructured":"Chesnut III CH, Skag A, Christiansen C et al. (2004) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a between-dose interval greater than 2 months: results from the BONE study. J Bone Miner Res (in press)"},{"key":"1602_CR28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","volume":"11","author":"Garnero","year":"1996","unstructured":"Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD (1996) Increased bone turnover in late menopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337\u2013349","journal-title":"J Bone Miner Res"},{"key":"1602_CR29","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","volume":"9","author":"Russell","year":"1999","unstructured":"Russell RGG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9:S66\u2212S80","journal-title":"Osteoporos Int"},{"key":"1602_CR30","first-page":"1693","volume":"79","author":"Garnero","year":"1994","unstructured":"Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693\u22121700","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR31","first-page":"1399","volume":"76","author":"Harris","year":"1993","unstructured":"Harris ST, Gertz BJ, Genant HK et al. (1993) The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399\u22121406","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR32","first-page":"1890","volume":"86","author":"Harris","year":"2001","unstructured":"Harris ST, Eriksen EF, Davidson M et al. (2001) Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86:1890\u22121897","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s001980070083","volume":"11","author":"Raisz","year":"2000","unstructured":"Raisz L, Smith JA, Trahiotis M et al. (2000) Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 11:615\u2212620","journal-title":"Osteoporos Int"},{"key":"1602_CR34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"Reginster","year":"2000","unstructured":"Reginster JY, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83\u221291","journal-title":"Osteoporos Int"},{"key":"1602_CR35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA et al. (2003) Relationship of early changes in bone resorption to reduction of fracture risk with risedronate. J Bone Miner Res 18:1051\u20131056","journal-title":"J Bone Miner Res"},{"key":"1602_CR36","first-page":"521","volume":"13","author":"Bauser","year":"2000","unstructured":"Bauser DC, Black DM, Garnero P et al. (2000) Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: the Fracture Intervention Trial. Osteoporos Int 13:521","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-004-1602-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-004-1602-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-004-1602-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-004-1602-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T18:35:37Z","timestamp":1581964537000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-004-1602-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,8]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1007\/s00198-004-1602-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,8]]}}}